Recent tumor models treated with A2AR antagonists have shown significant inhibition of spheroid growth in primary breast cancer patients (122), suggesting that adenosine and its related pathways may be promising targets for future immunotherapy. This evidence concerns the gene ADORA2A and neoplasm.